Hortensia Ferrero, Ph.D.

Treatment and Diagnosis of Uterine Diseases Research Group Leader

FIVI Valencia

Hortensia Ferrero, Ph.D.

Biografía

Dr. Hortensia Ferrero is a full-time investigator at FIVI-INCLIVA through a Sara Borrell Grant by Health Institute Carlos III and research group leader for treatment and diagnosis of uterine diseases at IVI Foundation in Valencia. She obtained her Bachelors degree form the University of Valencia in 2006, with a major in Biology. She then obtained a Master’s Degree in Biotechnology and Biomedicine (2008), focusing on Human Reproductive Biology. She carried out her PhD studies with a PFIS fellowship granted by Health Institute Carlos III. In 2013, she worked six months with Dr. D. Stephen Charnock-Jones’ group at University of Cambridge in the Department of Obstetrics and Gynaecology, in the UK, supported by a grant by Health Institute Carlos III. She received her PhD degree in Biotechnology with special international mention, in 2014 from University of Valencia. Her thesis project on the angiogenic process regulating the corpus luteum in physiological and pathological conditions recieved an Extraordinary Award in 2015.

Subsequently, Dr. Ferrero conducted studies on the diagnosis and treatment of endometriosis using eutopic endometrial samples from patients with endometriosis, and heterologous and homologous animal model of this disease.

As a researcher, Dr. Ferrero has published in leading reproductive journals, such as JCEM, Human Reproduction, Fertility and Sterility, Placenta, Biology of Reproduction, and presented in several national and international meetings in the field of Reproductive Medicine, including ESHRE (European Society of Human Reproduction and Embryology) and SRI (Society of Reproductive Investigation).

Dr. Ferrero also participates as researcher in competitive project-grants as emerging researcher (Valencian State Governments) and researcher (Spanish Ministry of Economy and Competitiveness), besides acting as regular reviewer in different international journals, such as Human Reproduction, and Fertility and Sterility.

Dr. Ferrero has been involved in teaching in postgraduate courses since 2009, in Human Reproduction Module form the Master’s Degree in Biotechnology of Assisted Human Reproduction. In addition, she is supervising a doctoral thesis on uterine fibroids, since 2016.

Read more

Formación

B.Sc. University of Valencia, Spain (2006)
MSc in Biomedicine and Biotecnology University of Alicante (2006-2008)
Fellowship University of Cambridge, UK (2013)
PhD in Biotecnology University of Valencia, Spain (2014)

Honores y reconocimientos

SRI Travel Award for “NGS of oocytes from endometriosis patients reveals a differential transcriptomic pattern" 2019
Sara Borrell Grant by Heath Institute Carlos III 2016-2019
PhD Extraordinary Award 2015
PFIS felowship Grant by Heath Institute Carlos III 2009-2013

Publicaciones


  • Evaluation of the antiproliferative, proapoptotic, and antiangiogenic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of leiomyoma.
    García-Pascual CM, Ferrero H, Juarez I, Martínez J, Villanueva A, Pozuelo-Rubio M, Soengas M, Tormo D, Simón C, Gómez R, Pellicer A.
    Fertil Steril. 2016:105(2):529-38.

  • Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometriosis.
    García-Pascual CM, Martínez J, Calvo P, Ferrero H, Villanueva A, Pozuelo-Rubio M, Soengas M, Tormo D, Simón C, Pellicer A, Gómez R.
    Fertil Steril. 2015:104(5):1310-8.

  • Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.
    Ferrero H, García-Pascual CM, Pellicer N, Simón C, Pellicer A, Gómez R.
    Reprod Biol Endocrinol. 2015:17;13:104

  • Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.
    Ferrero H, García-Pascual CM, Gómez R, Delgado-Rosas F, Cauli O, Simón C, Gaytán F, Pellicer A.
    Fertil Steril. 2014:101(5):1411-8.

  • Inhibition of Delta-like 4 mediated signaling induces abortion in mice due to deregulation of decidual angiogenesis.
    García-Pascual CM, Ferrero H, Zimmermann RC, Simón C, Pellicer A, Gómez R. Placenta. 2014:35(7):501-8.

  • Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H, García-Pascual CM, Gaytán M, Morales C, Simón C, Gaytán F, Pellicer A, Gómez R.
    Fertil Steril. 2014:102(5):1468-1476.


  • Delta-like ligand 4 regulates vascular endothelial growth factor receptor 2-driven luteal angiogenesis through induction of a tip/stalk phenotype in proliferating endothelial cells.
    García-Pascual CM, Zimmermann RC, Ferrero H, Shawber CJ, Kitajewski J, Simón C, Pellicer A, Gómez R.
    Fertil Steril. 2013:100(6):1768-76.

  • Efficiency and purity provided by the existing methods for the isolation of luteinized granulosa cells: a comparative study.
    Ferrero H, Delgado-Rosas F, Garcia-Pascual CM, Monterde M, Zimmermann RC, Simón C, Pellicer A, Gómez R.
    Hum Reprod. 2012:27(6):1781-9.

  • Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
    Gómez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, Zimmermann RC, Simón C, Gaytan F, Pellicer A.
    J Clin Endocrinol Metab. 2011:96(8):2484-92

  • The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.
    Delgado-Rosas F, Gómez R, Ferrero H, Gaytan F, Garcia-Velasco J, Simón C, Pellicer A.
    Reproduction. 2011:142(5):745-55

Read more

Presentations

Read more
Cerrar menú